Stock Market Reviews

PRAX (Praxis Precision Medicines, Inc.) News

Get the latest news, insights, and market updates on PRAX (Praxis Precision Medicines, Inc.). Explore the news page 6 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Health Care Roundup: Market Talk
  Find insight on the Praxis Precision Medicines, Novo Nordisk, Indonesian healthcare sector, Monash IVF and more in the latest Market Talks covering the health care sector.
  Dec 5, 2025 - $PRAX
• Praxis Surges 31%, Hitting Another 3-Year High, On A Surprise Win In Epilepsy
  Praxis Precision Medicines shares shot skyward Friday after the company stopped an epilepsy study early due to strong effectiveness.
  Dec 5, 2025 - $PRAX
• Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies
  Successful interim analysis triggered early stop for efficacy Topline study results to be shared at the American Epilepsy Society Annual Meeting on December 6, 2025 Praxis confirms an upcoming meeting with the FDA to discuss the results and NDA path BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characteri
  Dec 4, 2025 - $PRAX
• Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor
  Praxis confirms plans to submit the essential tremor NDA for ulixacaltamide in early 2026BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the successful completion of its pre-NDA (New Drug Application) meeting with the FDA, including
  Dec 4, 2025 - $PRAX
• Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  BOSTON, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on December 1, 2025, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 3,594 shares of its common stock to six
  Dec 3, 2025 - $PRAX
• Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting
  BOSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into therapies for central nervous system (CNS) disorders driven by neuronal excitation-inhibition imbalance, today announced they will present the latest preclinical and clinical data and progress on trials across its precision epilepsy pipeline at the American Epilepsy Society Annual (AES) Meeting, December 5-9, 2025, in Atlanta, Geo
  Nov 24, 2025 - $PRAX
• Praxis Precision Medicines to Participate in Upcoming Fireside Chat
  BOSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that HCWainwright analyst Doug Tsao will host an expert call on Deep Dive into Praxis’ Ulixacaltamide Data with statistician Prof. Chuck McCullogh, University of California, San Francis
  Nov 20, 2025 - $PRAX
• Here Are Wednesday’s Top Wall Street Analyst Research Calls: DoorDash, Freeport-McMoRan, GitLab, Home Depot, Medtronic, Molson-Coors, and More
  Pre-Market Stock Futures: Futures are trading higher this morning, as all the major indices once again closed lower on Tuesday, marking the fourth straight day of losses. The Dow Jones Industrials closed down 1.07% at 46,091, while the S&P 500 was last seen at 6617, down 0.83%. The NASDAQ, which has been hit the hardest ... Here Are Wednesday’s Top Wall Street Analyst Research Calls: DoorDash, Freeport-McMoRan, GitLab, Home Depot, Medtronic, Molson-Coors, and More
  Nov 19, 2025 - $PRAX
• High Growth Tech Stocks in US for November 2025
  As the tech-heavy Nasdaq faces its worst week since the 'Liberation Day' tariffs, with cooling AI sentiment and valuation concerns weighing heavily on the sector, investors are closely monitoring economic indicators and Federal Reserve actions amid a precarious labor market. In this environment of heightened volatility, identifying high-growth tech stocks requires careful consideration of companies that demonstrate resilience through innovation and adaptability in response to shifting market...
  Nov 7, 2025 - $PRAX
• Exploring 3 High Growth Tech Stocks in the US Market
  As of November 6, 2025, the United States market has been experiencing volatility with major stock indexes like the Nasdaq and S&P 500 closing lower due to resurfacing concerns about AI valuations and a significant uptick in job cuts reported for October. In this environment of fluctuating economic indicators and heightened scrutiny on tech valuations, identifying high growth tech stocks involves looking at companies that demonstrate resilience through innovation and adaptability in their...
  Nov 7, 2025 - $PRAX